Unravelling Cell Cycle and Ontogeny Transcriptional Heterogeneity in Hematopoietic Stem Cells through Integrated Single Cell RNA-Seq
Povinelli B. et al, (2017), BLOOD, 130
Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: an interview with Adam Mead
Mead A., (2017), FUTURE ONCOLOGY, 13, 2401 - 2404
Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program.
Loughran SJ. et al, (2017), The Journal of Experimental Medicine, 214, 3085 - 3104
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN. et al, (2017), Blood, 130, 1889 - 1897
Single cell analysis of normal and leukemic hematopoiesis.
Povinelli BJ. et al, (2017), Molecular aspects of medicine
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN. et al, (2017), Leukemia, 31, 1660 - 1660
Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.
Mead AJ. et al, (2017), The Journal of experimental medicine, 214, 2005 - 2021
COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS
Louka E. et al, (2017), HAEMATOLOGICA, 102, 265 - 265
COMPARISONS OF PATIENT MANAGEMENT IN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM THE INTERNATIONAL LANDMARK SURVEY
Harrison C. et al, (2017), HAEMATOLOGICA, 102, 813 - 814
COMPARISONS OF SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM THE INTERNATIONAL LANDMARK SURVEY
Harrison C. et al, (2017), HAEMATOLOGICA, 102, 815 - 816
DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM
Norfo R. et al, (2017), HAEMATOLOGICA, 102, 149 - 150
RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR
O'Byrne S. et al, (2017), HAEMATOLOGICA, 102, 80 - 80
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.
Giustacchini A. et al, (2017), Nat Med, 23, 692 - 702
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA. et al, (2017), Lancet Haematol, 4, e225 - e236
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN. et al, (2017), Leukemia, 31, 527 - 528
Guideline for the investigation and management of eosinophilia
Butt NM. et al, (2017), British Journal of Haematology, 176, 553 - 572
Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors.
Luis TC. et al, (2016), Nat Immunol, 17, 1424 - 1435
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Harrison CN. et al, (2016), Leukemia and Lymphoma, 57, 2259 - 2267